尼妥珠单抗在局部晚期食管癌治疗中的应用进展

Therapeutic progress of nimotuzumab in local advanced esophageal carcinoma

局部晚期食管癌(local advanced esophageal carcinoma,LAEC)无法通过手术根治,目前首选的治疗方法是根治性同期化放疗,但远期生存率仍不理想。尼妥珠单抗是一种新型人表皮生长因子受体单克隆抗体,细胞实验证实该药与化、放疗具有协同增效作用,近年来对该药与化、放疗联合治疗局部晚期食管癌的研究逐年增加,本文旨在对尼妥珠单抗治疗局部晚期食管癌的最新进展进行综述。

As an inoperable disease,local advanced esophageal carcinoma( LAEC) is currently treated with definitive radiotherapy and/or chemotherapy,but the long-term survival rate still poor. Nimotuzumab,a newly-developed monoclonal antibody against human epidermal growth factor receptor has been proved to be synergetic with chemotherapy and radiotherapy in vitro. Recently,a growing body of data has shown that nimotuzumab may have a role in the treatment of LAEC. Herein,we reviewed the up-to-date researches in this field.